According to filings with the U.S. Securities and Exchange Commission, Asher Biotherapeutics is raising up to $54,999,990.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Craig Gibbs played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Asher Biotherapeutics
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.

To learn more about Asher Biotherapeutics, visit http://www.asherbio.com/

Contact:
Craig Gibbs, Chief Executive Officer
650-628-8110
https://www.linkedin.com/in/crgibbs/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.